Generic Name: luspatercept
Brand Name: Reblozyl
Manufacturer: Celgene Inc. / Bristol-Myers Squibb Canada Co.
Therapeutic Area: beta-thalassemia associated anemia
Indications: For the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia
Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with -thalassemia associated anemia who require red blood cell (RBC) transfusions.
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient/clinician input open | October 29, 2020 |
| Call for patient/clinician input closed | December 17, 2020 |
| Clarification:
- Patient input submission received from the Thalassemia Foundation of Canada and Canadian Organization for Rare Disorders (CORD) |
|
| Submission received | November 26, 2020 |
| Submission accepted | December 10, 2020 |
| Review initiated | December 11, 2020 |
| Clarification:
- Selected for CADTH/INESSS Joint Clinician Engagement |
|
| Draft CADTH review report(s) provided to sponsor for comment | March 09, 2021 |
| Deadline for sponsors comments | March 18, 2021 |
| CADTH responses on draft review report(s) provided to sponsor | April 09, 2021 |
| Expert committee meeting (initial) | April 21, 2021 |
| Draft recommendation issued to sponsor | May 03, 2021 |
| Draft recommendation posted for stakeholder feedback | May 13, 2021 |
| End of feedback period | May 28, 2021 |